The FDA approved the first non-opioid treatment for opioid withdrawal symptom management in adults.
Here are three things to know.
1. Lucemyra (lofexidine hydrochloride) may lessen the severity of opioid withdrawal symptoms; it is only approved for treatment for up to 14 days and may not completely prevent withdrawal symptoms.
2. Lucemyra is an oral, selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine, which is believed to play a role in many opioid withdrawal symptoms.
3. An independent FDA advisory committee supported approving Lucemyra in March.
The treatment had fast-track designation and was reviewed under the FDA's priority review process.
More articles on practice management:
The CORE Institute plants roots in new medical campus: 3 takeaways
Orthopedic surgeon Dr. Armin Tehrany now a NYPD police surgeon: 5 things to know
Primary care compensation rose at rate nearly double of specialty: 6 things to note